Supply Chain

Although Novartis earned approval from the Food and Drug Administration for its biosimilar drug Erelzi, the Swiss drugmaker said it will not hit the market before 2018 due to a patent dispute with Thousand Oaks, Calif.-based Amgen, reports Reuters.

Biogen updated the label for its best-selling oral multiple sclerosis drug Tecfidera to include a warning about risk of liver injury that can occur when taking the drug, reports Reuters.

Here are seven articles published by Becker's Hospital Review in the past week that offer insight on the pharmaceutical industry, top priorities for supply chain leaders in 2017 and more.

President Donald Trump and Rep. Elijah Cumming, D-Md., spoke on the phone Wednesday about prescription drug prices, according to the Washington Examiner.

While many Americans criticize high drug prices, few understand the complex system used to establish the cost of prescription medications, reports Dayton Daily News.

President Donald Trump on Monday signed an executive order to freeze all federal hiring. The order could create a lag in the Food and Drug Administration's approval processes as the agency is short almost 1,000 employees, reports Regulatory Focus.

Lake Forest, Ill.-based pharmaceutical company Hospira issued a voluntary recall of its injectable vancomycin hydrochloride due to the detection of particulate matter in a single vial, according to a Tuesday announcement from the Food and Drug Administration.

Tom Price, MD, President Trump's pick to head HHS, may have opened the door to a new drug pricing system during his hearing with the Senate finance committee this week, reports Bloomberg.

President Trump's newest potential pick to head the Food and Drug Administration, Joseph Gulfo, MD, believes agency changes could help reign in high drug costs.

New Brunswick, N.J.-based Johnson & Johnson will acquire Swiss biotechnology company Actelion for $30 billion, reports The New York Times.